| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Revenue | $9.0M | -35.5% |
| R&D Expense | $129.5M | +461.1% |
| SG&A Expense | $33.0M | +67.7% |
| Operating Income | -$305.8M | -179.2% |
| Income Tax | $0 | — |
| Net Income | -$293.0M | -174.3% |
| EPS (Basic) | -$5.00 | +7.1% |
| EPS (Diluted) | -$5.00 | +7.1% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $143.4M | +45.3% |
| Current Assets | $221.3M | +53.0% |
| Total Assets | $240.2M | +61.7% |
| Current Liabilities | $54.3M | +148.8% |
| Total Liabilities | $59.1M | +106.1% |
| Stockholders' Equity | $181.2M | +51.1% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$110.8M | -1364.0% |
| Capital Expenditures | $7.2M | +763.2% |
| Investing Cash Flow | -$85.1M | -179.0% |
| Financing Cash Flow | $240.5M | +106.6% |
| Free Cash Flow | -$118.0M | -1304.5% |